Efficacy Clinical Trial
Official title:
A Phase II Study of Gemcitabine in Combination With Oxaliplatin as First Line Chemotherapy in Patients With Inoperable Biliary Tract Adenocarcinoma
Verified date | May 2009 |
Source | Soonchunhyang University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | South Korea: Institutional Review Board |
Study type | Interventional |
The role of systemic chemotherapy in advanced biliary tract cancer (BTC) is known to be very limited although various single-agent or combination therapies had been tested. However, there is a possibility that palliative chemotherapy induce prolong survival and improve quality of life in advanced BTC based on several studies. A GERCOR study showed the promising result of gemcitabine in combination with oxaliplatin as first line chemotherapy in advanced BTC. Therefore, this phase II trial was planned to investigate efficacy and toxicity of combination chemotherapy with gemcitabine and dose adjusted oxaliplatin in patients with inoperable BTC in Korea.
Status | Completed |
Enrollment | 40 |
Est. completion date | March 2009 |
Est. primary completion date | March 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients with histologically or cytologically confirmed biliary tract adenocarcinoma 2. Inoperable disease as defined by: - Localized disease in a portion of the liver that does not allow the possibility of complete surgical removal of the tumor with a clear resection margin. - Presence of metastatic lesion - Unresectable recurrent tumor after curative resection - anatomically resectable but inoperable associated with medical condition 3. Biliary obstruction controlled 4. Minimum life expectancy of 12 weeks. 5. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) or evaluable lesion present by imaging study 6. Age over 18 years 7. ECOG performance status of * 2. 8. Adequate organ function as evidenced by the following; Absolute neutrophil count > 1.5 x 109/L; platelets > 100 x 109/L; total bilirubin =3xUNL; AST and/or ALT < 5x UNL; Creatinine< 1.5mg/dl or creatinine clearance >50 ml/mins 9. Consent form signed and dated prior to study specific procedures. 10. Subject able to comply with the scheduled follow-up and with the management of toxicities. Exclusion Criteria: 1. Decompensated Cirrhosis or stage C (Index > 10) according to the Child-Pugh Classification 2. Prior systemic chemotherapy 3. Subject with reproductive potential (M/F) not using adequate contraceptive measures. 4. Pregnancy and breast-feeding. 5. Other serious illness or medical condition, notably heart or lung failure, active uncontrolled infection (infection requiring antibiotics). 6. Past or concurrent history of other neoplasm, except curatively treated basal cell skin cancer or adequately treated in-situ carcinoma of the cervix. 7. Symptomatic or uncontrolled brain metastasis 8. Other concomitant anticancer agent, including Tamoxifen and Interferon. 9. Subjects who cannot be regularly followed up for psychological, social, familial or geographic reasons. 10. Participation in another clinical study or within 30 days before inclusion. 11. History of severe hypersensitivity reactions to gemcitabine or oxaliplatin |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Soonchunhyang University Bucheon Hospital | Bucheon | Kyunggi |
Lead Sponsor | Collaborator |
---|---|
Soonchunhyang University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1) To estimate the overall response rate after treatment with gemcitabine and oxaliplatin in patients with advanced biliary tract adenocarcinoma | every 4 cycles | Yes | |
Secondary | 1) To evaluate the safety and tolerability of the treatment combination. 2) To estimate the time to progression and the duration of overall response. 3) To estimate overall tumor growth control rate (CR, PR plus SD). 4) To estimate overall survival. | Overall survival is defined from the first day of treatment to the date of death. Time to progression is defined from the first day of treatment to the date of tumor progression assessed by CT scan or MRI. | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT00944268 -
Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety
|
Phase 3 | |
Recruiting |
NCT05580159 -
New Generation mRNA Booster Vaccine Against Emerging VOCs
|
Phase 3 | |
Completed |
NCT05427305 -
TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Active, not recruiting |
NCT05686161 -
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
|
Phase 3 | |
Recruiting |
NCT06284746 -
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT04260113 -
Apatinib for Inoperable Advanced Chondrosarcoma
|
N/A | |
Recruiting |
NCT06120712 -
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04002440 -
Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight
|
N/A | |
Recruiting |
NCT02693587 -
Misodel or Angusta for Induction of Labour?
|
N/A | |
Completed |
NCT01194453 -
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05276557 -
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
|
Phase 3 | |
Recruiting |
NCT06205758 -
Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency
|
||
Recruiting |
NCT06122454 -
A Phase Ic/IIb Study to Evaluate the Efficacy,Safety and Pharmacokinetics of HST in Patients With CHB
|
Phase 1/Phase 2 | |
Recruiting |
NCT05913271 -
Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure
|
||
Recruiting |
NCT05999656 -
Human Cord Blood Mononuclear Cells in the Treatment of Refractory Diabetic Foot
|
N/A | |
Recruiting |
NCT05731258 -
Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
|
||
Recruiting |
NCT03908138 -
RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
|
Phase 4 | |
Completed |
NCT05648799 -
Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia) in Healthy Volunteers and Outpatients With COVID-19
|
N/A | |
Recruiting |
NCT03377933 -
The Effects Probiotic Has on Gastromicroecology and Combined With Quadruple Regimen for H Pylori Infection
|
N/A | |
Recruiting |
NCT04069780 -
Suprachoroidal Injection of Triamcinolone Acetonide for Management of Diabetic Macular Edema
|
N/A |